|
Feb 20
|
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
|
|
Feb 19
|
SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over
|
|
Feb 13
|
Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon
|
|
Feb 13
|
SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg
|
|
Feb 13
|
SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25
|
|
Feb 12
|
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
|
|
Feb 11
|
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
|
|
Feb 11
|
Germany’s Merck in Talks to Buy SpringWorks Therapeutics
|
|
Jan 3
|
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Nov 15
|
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report
|
|
Nov 13
|
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Nov 12
|
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
|
|
Nov 12
|
SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study
|
|
Nov 12
|
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
|
Nov 11
|
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
|
|
Nov 11
|
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
|
|
Jul 29
|
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
|
|
Jul 23
|
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
|
|
May 23
|
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 8
|
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
|